Correlation Between Samsung Biologics and Korea Ratings

Can any of the company-specific risk be diversified away by investing in both Samsung Biologics and Korea Ratings at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Samsung Biologics and Korea Ratings into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Samsung Biologics Co and Korea Ratings Co, you can compare the effects of market volatilities on Samsung Biologics and Korea Ratings and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Samsung Biologics with a short position of Korea Ratings. Check out your portfolio center. Please also check ongoing floating volatility patterns of Samsung Biologics and Korea Ratings.

Diversification Opportunities for Samsung Biologics and Korea Ratings

-0.53

Correlation Coefficient

Samsung Biologics  Korea Ratings

Excellent diversification

The 3 months correlation between Samsung and Korea is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Samsung Biologics Co and Korea Ratings Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Korea Ratings and Samsung Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Samsung Biologics Co are associated (or correlated) with Korea Ratings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Korea Ratings has no effect on the direction of Samsung Biologics i.e., Samsung Biologics and Korea Ratings go up and down completely randomly.

Pair Corralation between Samsung Biologics and Korea Ratings

Assuming the 90 days trading horizon Samsung Biologics is expected to generate 2.1 times less return on investment than Korea Ratings. In addition to that, Samsung Biologics is 2.38 times more volatile than Korea Ratings Co. It trades about 0.02 of its total potential returns per unit of risk. Korea Ratings Co is currently generating about 0.1 per unit of volatility. If you would invest  8,510,000  in Korea Ratings Co on September 1, 2024 and sell it today you would earn a total of  290,000  from holding Korea Ratings Co or generate 3.41% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Samsung Biologics Co  vs.  Korea Ratings Co

Samsung Biologics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Samsung Biologics Co are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Samsung Biologics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Korea Ratings

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Korea Ratings Co are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Korea Ratings is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Samsung Biologics and Korea Ratings

The main advantage of trading using opposite Samsung Biologics and Korea Ratings positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Samsung Biologics position performs unexpectedly, Korea Ratings can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Korea Ratings will offset losses from the drop in Korea Ratings' long position.

The idea behind Samsung Biologics Co and Korea Ratings Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.